Reevolt Pharma

Revolo Biotherapeutics is a clinical-stage biotechnology company focused on developing therapies that reset the immune system to treat autoimmune and allergic diseases. Unlike traditional immunosuppressants that broadly dampen immune activity, Revolo's approach aims to restore long-term immune homeostasis by inducing a regulatory environment. The company's lead candidates include IRL201102, a protein therapy for allergic rhinitis, and IRL201805, a peptide therapy for rheumatoid arthritis. By targeting the root cause of immune dysregulation, Revolo seeks to provide durable clinical benefits without the side effects associated with chronic immunosuppression.